

# EQUITIES

## ON THE MOVE CORPORATE PROFILES

### Acrongenomics, Inc.

OTC BB: AGNM



14 Rue Kleberg CH-1201 Geneva, Switzerland

Tel: +41 22 716 5300 • Fax: +41 22 716 5319

www.acrongen.com • manos@acrongen.com • angela@acrongen.com

#### TOP INVESTMENT HIGHLIGHTS

- ☑ Recently signed \$6.5 million joint development agreement with Molecular Vision Ltd.
- ☑ Patented BioLED technology allows doctors to make diagnosis faster and more accurately.
- ☑ BioLED technology will help advance Point of Care (POC) devices for on the spot diagnosis of diabetes management, STD's, cardiovascular diseases, and substances of abuse.
- ☑ BioLED technology has the potential to expand into other markets such as pharmaceuticals, environmental and bio-defense technologies.
- ☑ Distinguished scientific advisory board consists of some of Europe's most respected researchers.
- ☑ Highly experienced management team.
- ☑ Strategic alliance with Molecular Vision Ltd fuels growth.
- ☑ Headquartered in Switzerland and traded in the U.S., the company's international position opens up various markets as well as capital sources.
- ☑ Currently, portable diagnostic devices for POC testing have been hampered by the lack of suitable miniaturized, low-power consumption, optical detection systems, as well as high costs.

#### CORPORATE OVERVIEW

Acrongenomics, Inc. (OTCBB: AGNM) is a publicly traded company that focuses on investing and commercializing novel technology platforms concerning the Life Sciences sector. Acrongenomics brings novel and realistic concepts to market by transforming scientific innovations into tangible, customer-oriented applications. The company has its headquarters in Geneva, Switzerland.

As the global population escalates every year, medical providers are constantly seeking technologically advanced

products and processes from diagnostics to treatment to monitoring patient diseases. Acrongenomics anticipates the technological changes it will inevitably encounter, and strives to play an influential role in advancing medical technologies that will undoubtedly benefit the medical community around the world.

Acrongenomics is confident of its ability to satisfy its shareholders and employees by constantly evaluating its business strategy by collaborating with well-established research institutions

and investing in innovative scientific projects, converting them into commercial opportunities.

#### VISION AND GOALS

Acrongenomics' goal is to advance the Medical Diagnostics industry and accomplish industry-leading growth by establishing our technology platform worldwide. Through innovative and advanced medical diagnostic applications, we aim to provide the most efficient and sustainable means of delivering new value to the marketplace.

Acrongenomics is also committed to contribute to the human health and quality of life by exploring new scientific approaches and continuously considering:

- Business – By sponsoring new innovative ideas and transforming them into commercial opportunities.
- Social Welfare – By providing the market with superior technology designed to serve the common good.
- Our People – By expanding our qualified team of business professionals to further support our technology pipeline.

#### STRATEGIC ALLIANCES

Acrongenomics utilizes its extensive international network and qualified management team to scout out and invest in dynamic research projects. To that extent Acrongenomics has established a Strategic Alliance with the UK based Molecular Vision Ltd.

Molecular Vision is a spin-out company of Imperial Innovations Ltd. The company was founded in 2002 in order to meet a clearly defined demand in the medical diagnostics, biosensors and analytical instrumentations markets: the need for miniaturized chemical and biological detectors offering high sensitivity and functionality at low cost. The company has directly addressed this

market demand by inventing a novel method for optical detection based on recent advances in organic electronics and light emitting diodes combined with microfluidics technology. The company has mainly focused on applying its technology to the medical diagnostics markets.

## BIOLED TECHNOLOGY

Terms like Lab-On-a-Chip (LOC), Point-of-Care (POC) testing and miniaturized Total Analysis Systems ( $\mu$ TAS) describe the same concept; specialized, light weight, readily portable and easy to use devices, designed to perform complex biological tests at the site where they are most needed. These tests normally require specialized laboratories equipped with bulky and expensive instruments. POC testing constitutes a "stand alone" new market with impressive growth potential that may/or may not complement the already established laboratory testing. The main market driving force is the enhanced portability and networking capabilities that lead to improved patient's quality of life and increased independence from organized health-care facilities.

Low cost, organic semiconductor polymers with tunable optical properties is the answer provided by Acroengenomics and Molecular Vision. Optical detection is provided by polymer Light Emitting Diodes (pLEDs) which are fully compatible with microfluidic chip technology. The combination of the two technologies is used for the development of a "readily portable" microfluidic and pLED platform (BioLED technology) that is initially applied to the development of POC microchips for the quantitative and qualitative analysis of medical conditions with high sensitivity and functionality at low cost.

## TECHNOLOGY ADVANTAGES:

- Electronic readout gives fast, unambiguous diagnosis

- Designed to analyze complex materials such as blood, urine, and saliva
- Ability to perform multiple tests on a single microchip
- Low manufacturing costs
- Product is easy to use, ideal for over the counter
- Technology has potential for other uses

## CURRENT – POC DIAGNOSTICS

Following a primary market research, a number of potential POC diagnostic device applications were evaluated in terms of feasibility, market needs, revenue generating potential, market growth rate and competition. Among these, four disease areas were chosen to be our primary targets for BioLED device development. These POC devices will enable on-the-spot quantitative and qualitative diagnosis from a few drops of blood, urine or saliva for:

- Diabetes Management (Kidney Markers)
- Sexually Transmitted Diseases (STDs)
- Cardiovascular Diseases (Cardiac Markers)
- Substances of Abuse

## FUTURE

BioLED Technology has the potential for the development of a vast spectrum of applications that may include:

- Pharmaceuticals – Drug discovery, drug testing (high throughput screening)
- Environmental technology – Soil (also agriculture), water and air quality measurements
- Veterinary Medicine – Early disease detection in animals and location of the source of pathogens of public health threats such as mad cow disease and avian flu

- Biodefense – Portable devices which sample the air for biowarfare agents e.g. anthrax spores etc.
- Forensics – Automated processing of crime scene forensic evidence
- Food industry – Food diagnostics, packaging (smart sensors), functional food testing

## MANAGEMENT

**Constantine Poullos, LLM,**  
*President and member of the Board of Directors*

**Platon Tzouvalis, MSc,**  
*Vice President, Member of the Board of Directors and Scientific Advisory Board*

**Manos Topoglidis, Ph.D.,**  
*Member of the Board of Directors and Scientific Advisory Board*

---

This corporate profile is based upon information provided by management of Acroengenomics, Inc. The information is not intended to be, and shall not constitute, an offer to sell or solicitation of any offer to buy any security. It is intended for information only, and to increase awareness of Acroengenomics, Inc.'s services. Safe Harbor Statement: The statements in this document relating to future product availability, collaboration and partnership, and positive direction are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the aspects anticipated by these forward-looking statements may not, in fact, occur. Factors that could cause or contribute to such differences include, but are not limited to, contractual difficulties, demand for Acroengenomics, Inc.'s products, the future market price of Acroengenomics, Inc. common stock, and the Company's ability to obtain necessary future financing. EQUITIES Magazine was paid \$7,500 by Acroengenomics, Inc. to write and print this profile in the Summer issue of EQUITIES Magazine. Before investing in any security, you are strongly advised to review all public filings of the issuer of such security, which can be found at [www.sec.gov](http://www.sec.gov), as well as the warnings published by the Securities and Exchange Commission at <http://www.sec.gov/investor.shtml>.